{"id":386255,"date":"2020-11-20T17:03:20","date_gmt":"2020-11-20T22:03:20","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=386255"},"modified":"2020-11-20T17:03:20","modified_gmt":"2020-11-20T22:03:20","slug":"investor-alert-kaplan-fox-continues-to-investigate-boston-scientific-corporation-bsx","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-kaplan-fox-continues-to-investigate-boston-scientific-corporation-bsx\/","title":{"rendered":"Investor Alert: Kaplan Fox Continues To Investigate Boston Scientific Corporation (BSX)"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">NEW YORK<\/span>, <span class=\"xn-chron\">Nov. 20, 2020<\/span> \/PRNewswire\/ &#8212;\u00a0Kaplan Fox &amp; Kilsheimer LLP (<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2989741-1&amp;h=2783524245&amp;u=http%3A%2F%2Fwww.kaplanfox.com%2F&amp;a=www.kaplanfox.com\" rel=\"nofollow noopener noreferrer\">www.kaplanfox.com<\/a>) has been \u00a0investigating potential claims against Boston Scientific Corporation (NYSE: BSX)\u00a0(&#8220;BSX&#8221; or the &#8220;Company&#8221;) for violations of the federal securities laws.\u00a0 <\/p>\n<p>BSX&#8217;s Lotus Edge is a transcatheter aortic value replacement. The FDA approved the Lotus Edge in <span class=\"xn-chron\">April 2019<\/span> for patients with severe aortic stenosis, while clinical trials were run in 2020 for patients with intermediate risk.\u00a0 <\/p>\n<p>On <span class=\"xn-chron\">November 17, 2020<\/span>, before the market opened, BSX announced &#8220;it initiated a global, voluntary recall of all unused inventory of the LOTUS Edge<sup>\u2122<\/sup>\u00a0Aortic Valve System due to complexities associated with the product delivery system.&#8221;\u00a0 Further, the Company disclosed that &#8220;[g]iven the additional time and investment required to develop and reintroduce an enhanced delivery system, the company has chosen to retire the entire LOTUS product platform immediately. All related commercial, clinical, research &amp; development and manufacturing activities will also cease.&#8221;\u00a0 BSX&#8217;s stated that its decision &#8220;is expected to result in estimated total pre-tax GAAP charges of approximately\u00a0$225 million\u00a0to\u00a0$300 million\u00a0due to inventory, fixed asset, intangible asset and certain other exit charges and approximately\u00a0$100 million\u00a0to\u00a0$150 million\u00a0of these charges will impact the company&#8217;s adjusted results.&#8221;<\/p>\n<p>On <span class=\"xn-chron\">November 17, 2020<\/span>, BSX shares declined from a closing price on <span class=\"xn-chron\">November 16, 2020<\/span> of <span class=\"xn-money\">$38.03<\/span> per share, to close at <span class=\"xn-money\">$35.07<\/span> per share, a decline of <span class=\"xn-money\">$2.96<\/span> per share or approximately 8%, on heavier than usual volume.<\/p>\n<p>If you purchased shares of BSX and would like to discuss our investigation, please contact us by emailing <a target=\"_blank\" href=\"mailto:jcampisi@kaplanfox.com\" rel=\"nofollow noopener noreferrer\">jcampisi@kaplanfox.com<\/a> or by calling 212-329-8571.\u00a0 <\/p>\n<p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.<\/p>\n<p>\n        <span class=\"xn-person\">Kaplan Fox<\/span> &amp; Kilsheimer LLP, with offices in <span class=\"xn-location\">New York<\/span>, <span class=\"xn-location\">San Francisco<\/span>, <span class=\"xn-location\">Los Angeles<\/span>, <span class=\"xn-location\">Chicago<\/span> and <span class=\"xn-location\">New Jersey<\/span>, has decades of experience in prosecuting investor class actions. For more information about <span class=\"xn-person\">Kaplan Fox<\/span> &amp; Kilsheimer LLP, you may visit our website at <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2989741-1&amp;h=2783524245&amp;u=http%3A%2F%2Fwww.kaplanfox.com%2F&amp;a=www.kaplanfox.com\" rel=\"nofollow noopener noreferrer\">www.kaplanfox.com<\/a>.\u00a0 If you have any questions about your rights or interests, please contact: <\/p>\n<p>\n        <span class=\"xn-person\">Jeffrey P. Campisi<\/span><br \/>\n        <br \/>\n        <span class=\"xn-person\">KAPLAN FOX<\/span> &amp; KILSHEIMER LLP<br \/>850 Third Avenue, 14th Floor<br \/><span class=\"xn-location\">New York<\/span>, New York\u00a010022<br \/>(212) 329-8571<br \/>(212) 687-1980<br \/>Fax: (212) 687-7714<br \/>E-mail: <a target=\"_blank\" href=\"mailto:jcampisi@kaplanfox.com\" rel=\"nofollow noopener noreferrer\">jcampisi@kaplanfox.com<\/a><\/p>\n<p>\n        <span class=\"xn-person\">Laurence D. King<\/span><br \/>\n        <br \/>\n        <span class=\"xn-person\">KAPLAN FOX<\/span> &amp; KILSHEIMER LLP<br \/>350 Sansome Street, Suite 400 <br \/><span class=\"xn-location\">San Francisco<\/span>, California\u00a0 94104<br \/>(415) 772-4700<br \/>Fax:\u00a0 (415) 772-4707<br \/>E-mail: <a target=\"_blank\" href=\"mailto:lking@kaplanfox.com\" rel=\"nofollow noopener noreferrer\">lking@kaplanfox.com<\/a><\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=DC99900&amp;sd=2020-11-20\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/investor-alert-kaplan-fox-continues-to-investigate-boston-scientific-corporation-bsx-301178274.html\">http:\/\/www.prnewswire.com\/news-releases\/investor-alert-kaplan-fox-continues-to-investigate-boston-scientific-corporation-bsx-301178274.html<\/a><\/p>\n<p>SOURCE  <span class=\"xn-person\">Kaplan Fox<\/span> &amp; Kilsheimer LLP<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=DC99900&amp;Transmission_Id=202011201700PR_NEWS_USPR_____DC99900&amp;DateId=20201120\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire NEW YORK, Nov. 20, 2020 \/PRNewswire\/ &#8212;\u00a0Kaplan Fox &amp; Kilsheimer LLP (www.kaplanfox.com) has been \u00a0investigating potential claims against Boston Scientific Corporation (NYSE: BSX)\u00a0(&#8220;BSX&#8221; or the &#8220;Company&#8221;) for violations of the federal securities laws.\u00a0 BSX&#8217;s Lotus Edge is a transcatheter aortic value replacement. The FDA approved the Lotus Edge in April 2019 for patients with severe aortic stenosis, while clinical trials were run in 2020 for patients with intermediate risk.\u00a0 On November 17, 2020, before the market opened, BSX announced &#8220;it initiated a global, voluntary recall of all unused inventory of the LOTUS Edge\u2122\u00a0Aortic Valve System due to complexities associated with the product delivery system.&#8221;\u00a0 Further, the Company disclosed that &#8220;[g]iven the additional time and investment required to develop &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-kaplan-fox-continues-to-investigate-boston-scientific-corporation-bsx\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Investor Alert: Kaplan Fox Continues To Investigate Boston Scientific Corporation (BSX)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-386255","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Investor Alert: Kaplan Fox Continues To Investigate Boston Scientific Corporation (BSX) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-kaplan-fox-continues-to-investigate-boston-scientific-corporation-bsx\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Investor Alert: Kaplan Fox Continues To Investigate Boston Scientific Corporation (BSX) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK, Nov. 20, 2020 \/PRNewswire\/ &#8212;\u00a0Kaplan Fox &amp; Kilsheimer LLP (www.kaplanfox.com) has been \u00a0investigating potential claims against Boston Scientific Corporation (NYSE: BSX)\u00a0(&#8220;BSX&#8221; or the &#8220;Company&#8221;) for violations of the federal securities laws.\u00a0 BSX&#8217;s Lotus Edge is a transcatheter aortic value replacement. The FDA approved the Lotus Edge in April 2019 for patients with severe aortic stenosis, while clinical trials were run in 2020 for patients with intermediate risk.\u00a0 On November 17, 2020, before the market opened, BSX announced &#8220;it initiated a global, voluntary recall of all unused inventory of the LOTUS Edge\u2122\u00a0Aortic Valve System due to complexities associated with the product delivery system.&#8221;\u00a0 Further, the Company disclosed that &#8220;[g]iven the additional time and investment required to develop &hellip; Continue reading &quot;Investor Alert: Kaplan Fox Continues To Investigate Boston Scientific Corporation (BSX)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-kaplan-fox-continues-to-investigate-boston-scientific-corporation-bsx\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-20T22:03:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=DC99900&amp;sd=2020-11-20\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-kaplan-fox-continues-to-investigate-boston-scientific-corporation-bsx\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-kaplan-fox-continues-to-investigate-boston-scientific-corporation-bsx\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Investor Alert: Kaplan Fox Continues To Investigate Boston Scientific Corporation (BSX)\",\"datePublished\":\"2020-11-20T22:03:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-kaplan-fox-continues-to-investigate-boston-scientific-corporation-bsx\\\/\"},\"wordCount\":401,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-kaplan-fox-continues-to-investigate-boston-scientific-corporation-bsx\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=DC99900&amp;sd=2020-11-20\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-kaplan-fox-continues-to-investigate-boston-scientific-corporation-bsx\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-kaplan-fox-continues-to-investigate-boston-scientific-corporation-bsx\\\/\",\"name\":\"Investor Alert: Kaplan Fox Continues To Investigate Boston Scientific Corporation (BSX) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-kaplan-fox-continues-to-investigate-boston-scientific-corporation-bsx\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-kaplan-fox-continues-to-investigate-boston-scientific-corporation-bsx\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=DC99900&amp;sd=2020-11-20\",\"datePublished\":\"2020-11-20T22:03:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-kaplan-fox-continues-to-investigate-boston-scientific-corporation-bsx\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-kaplan-fox-continues-to-investigate-boston-scientific-corporation-bsx\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-kaplan-fox-continues-to-investigate-boston-scientific-corporation-bsx\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=DC99900&amp;sd=2020-11-20\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=DC99900&amp;sd=2020-11-20\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-kaplan-fox-continues-to-investigate-boston-scientific-corporation-bsx\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investor Alert: Kaplan Fox Continues To Investigate Boston Scientific Corporation (BSX)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Investor Alert: Kaplan Fox Continues To Investigate Boston Scientific Corporation (BSX) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-kaplan-fox-continues-to-investigate-boston-scientific-corporation-bsx\/","og_locale":"en_US","og_type":"article","og_title":"Investor Alert: Kaplan Fox Continues To Investigate Boston Scientific Corporation (BSX) - Market Newsdesk","og_description":"PR Newswire NEW YORK, Nov. 20, 2020 \/PRNewswire\/ &#8212;\u00a0Kaplan Fox &amp; Kilsheimer LLP (www.kaplanfox.com) has been \u00a0investigating potential claims against Boston Scientific Corporation (NYSE: BSX)\u00a0(&#8220;BSX&#8221; or the &#8220;Company&#8221;) for violations of the federal securities laws.\u00a0 BSX&#8217;s Lotus Edge is a transcatheter aortic value replacement. The FDA approved the Lotus Edge in April 2019 for patients with severe aortic stenosis, while clinical trials were run in 2020 for patients with intermediate risk.\u00a0 On November 17, 2020, before the market opened, BSX announced &#8220;it initiated a global, voluntary recall of all unused inventory of the LOTUS Edge\u2122\u00a0Aortic Valve System due to complexities associated with the product delivery system.&#8221;\u00a0 Further, the Company disclosed that &#8220;[g]iven the additional time and investment required to develop &hellip; Continue reading \"Investor Alert: Kaplan Fox Continues To Investigate Boston Scientific Corporation (BSX)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-kaplan-fox-continues-to-investigate-boston-scientific-corporation-bsx\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-20T22:03:20+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=DC99900&amp;sd=2020-11-20","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-kaplan-fox-continues-to-investigate-boston-scientific-corporation-bsx\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-kaplan-fox-continues-to-investigate-boston-scientific-corporation-bsx\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Investor Alert: Kaplan Fox Continues To Investigate Boston Scientific Corporation (BSX)","datePublished":"2020-11-20T22:03:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-kaplan-fox-continues-to-investigate-boston-scientific-corporation-bsx\/"},"wordCount":401,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-kaplan-fox-continues-to-investigate-boston-scientific-corporation-bsx\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=DC99900&amp;sd=2020-11-20","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-kaplan-fox-continues-to-investigate-boston-scientific-corporation-bsx\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-kaplan-fox-continues-to-investigate-boston-scientific-corporation-bsx\/","name":"Investor Alert: Kaplan Fox Continues To Investigate Boston Scientific Corporation (BSX) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-kaplan-fox-continues-to-investigate-boston-scientific-corporation-bsx\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-kaplan-fox-continues-to-investigate-boston-scientific-corporation-bsx\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=DC99900&amp;sd=2020-11-20","datePublished":"2020-11-20T22:03:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-kaplan-fox-continues-to-investigate-boston-scientific-corporation-bsx\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-kaplan-fox-continues-to-investigate-boston-scientific-corporation-bsx\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-kaplan-fox-continues-to-investigate-boston-scientific-corporation-bsx\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=DC99900&amp;sd=2020-11-20","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=DC99900&amp;sd=2020-11-20"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-kaplan-fox-continues-to-investigate-boston-scientific-corporation-bsx\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Investor Alert: Kaplan Fox Continues To Investigate Boston Scientific Corporation (BSX)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/386255","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=386255"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/386255\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=386255"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=386255"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=386255"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}